Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.

AURKA inhibition mimics BRCAness. Aging (Albany NY) (2017) 0.75

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22

Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95

Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31

ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res (2004) 6.38

Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther (2010) 5.92

XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell (2006) 5.62

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60

Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 5.56

Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell (2006) 5.33

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res (2006) 4.06

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 3.99

Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci (1994) 3.97

Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J (2009) 3.89

Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev (2002) 3.83

Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science (2012) 3.38

Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. Mol Cell (2004) 3.32

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res (2013) 3.25

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47

Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43

Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res (2000) 2.43

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res (2011) 2.35

Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science (2004) 2.25

Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genet (2010) 2.14

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04

BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci U S A (1997) 2.02

ADP-ribosylation of proteins. Enzymology and biological significance. Mol Biol Biochem Biophys (1987) 2.00

Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci (2012) 1.84

Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A (1996) 1.70

BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis. EMBO J (2009) 1.66

Preclinical versus clinical drug combination studies. Leuk Lymphoma (2008) 1.51

The DNA polymerase lambda is required for the repair of non-compatible DNA double strand breaks by NHEJ in mammalian cells. Nucleic Acids Res (2006) 1.51

BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ (1996) 1.45

Cancer translocations in human cells induced by zinc finger and TALE nucleases. Genome Res (2013) 1.44

Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res (2007) 1.42

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol (2015) 1.41

Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun (2014) 1.31

Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res (2010) 1.31

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol (2012) 1.31

Involvement of DNA polymerase mu in the repair of a specific subset of DNA double-strand breaks in mammalian cells. Nucleic Acids Res (2007) 1.27

HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle (2006) 1.25

Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene (2004) 1.24

PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol (2013) 1.23

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene (2013) 1.21

Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res (2007) 1.20

Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice. Oncogene (1998) 1.17

Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res (1997) 1.17

Sibling rivalry: competition between Pol X family members in V(D)J recombination and general double strand break repair. Immunol Rev (2004) 1.10

Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res (2005) 1.08

Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog (2005) 1.08

Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med (2010) 1.08

M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex. J Biol Chem (2003) 1.07

LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy. J Cell Sci (2012) 1.05

BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. Dev Cell (2012) 1.05

BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev Cell (2012) 1.02

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol (2013) 1.00

Evidence that the tumor-suppressor protein BRCA2 does not regulate cytokinesis in human cells. J Cell Sci (2010) 0.99

Centrosome abnormalities in ovarian cancer. Int J Cancer (2005) 0.98

Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem (2012) 0.97

Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan (2001) 0.93

The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy. Mol Cancer (2014) 0.91

Cernunnos-XLF, a recently identified non-homologous end-joining factor required for the development of the immune system. Curr Opin Allergy Clin Immunol (2006) 0.88

BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress. Cell Cycle (2013) 0.87

The V(D)J recombination/DNA repair factor artemis belongs to the metallo-beta-lactamase family and constitutes a critical developmental checkpoint of the lymphoid system. Ann N Y Acad Sci (2003) 0.86

Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. Oncogene (1998) 0.85

Aurora-A: a potential DNA repair modulator. Tumour Biol (2013) 0.84

Loss of BubR1 acetylation causes defects in spindle assembly checkpoint signaling and promotes tumor formation. J Cell Biol (2013) 0.83

PTN signaling: Components and mechanistic insights in human ovarian cancer. Mol Carcinog (2014) 0.82

Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents. Curr Protoc Pharmacol (2009) 0.81

Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases. Curr Opin Struct Biol (2012) 0.81

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer. PLoS One (2015) 0.80

Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol Cancer Ther (2014) 0.76

Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer. Mol Cancer Ther (2016) 0.75

Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget (2017) 0.75

Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget (2017) 0.75